|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GHRL |
Gene summary for GHRL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GHRL | Gene ID | 51738 |
| Gene name | ghrelin and obestatin prepropeptide | |
| Gene Alias | MTLRP | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9UBU3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51738 | GHRL | Pat02-B | Human | Stomach | GC | 1.59e-06 | 2.39e-02 | 0.0368 |
| 51738 | GHRL | Pat05-B | Human | Stomach | GC | 4.22e-05 | 1.48e-01 | -0.0353 |
| 51738 | GHRL | Pat06-B | Human | Stomach | GC | 6.41e-47 | 4.35e-01 | -0.1961 |
| 51738 | GHRL | Pat15-B | Human | Stomach | GC | 6.61e-09 | 2.43e-01 | -0.0778 |
| 51738 | GHRL | Pat24-B | Human | Stomach | GC | 2.39e-74 | 1.30e+00 | -0.1184 |
| 51738 | GHRL | Pat28-A | Human | Stomach | CSG | 3.50e-17 | 3.10e-01 | -0.2594 |
| 51738 | GHRL | Pat29-A | Human | Stomach | CAG with IM | 1.92e-44 | 1.13e+00 | -0.2769 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Esophagus | ESCC |  |
| Skin | AK |  |
| Skin | SCCIS |  |
| Skin | cSCC |  |
| Thyroid | HT |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007586 | Stomach | GC | digestion | 38/1159 | 137/18723 | 1.80e-15 | 1.22e-12 | 38 |
| GO:00226006 | Stomach | GC | digestive system process | 30/1159 | 104/18723 | 5.40e-13 | 2.10e-10 | 30 |
| GO:00070156 | Stomach | GC | actin filament organization | 67/1159 | 442/18723 | 7.96e-12 | 2.20e-09 | 67 |
| GO:00097436 | Stomach | GC | response to carbohydrate | 40/1159 | 253/18723 | 4.13e-08 | 2.85e-06 | 40 |
| GO:00342846 | Stomach | GC | response to monosaccharide | 37/1159 | 225/18723 | 4.67e-08 | 3.17e-06 | 37 |
| GO:00097466 | Stomach | GC | response to hexose | 36/1159 | 219/18723 | 7.14e-08 | 4.62e-06 | 36 |
| GO:00097496 | Stomach | GC | response to glucose | 33/1159 | 212/18723 | 8.93e-07 | 4.33e-05 | 33 |
| GO:00316676 | Stomach | GC | response to nutrient levels | 56/1159 | 474/18723 | 2.47e-06 | 1.06e-04 | 56 |
| GO:00713315 | Stomach | GC | cellular response to hexose stimulus | 25/1159 | 153/18723 | 7.68e-06 | 2.77e-04 | 25 |
| GO:00713265 | Stomach | GC | cellular response to monosaccharide stimulus | 25/1159 | 154/18723 | 8.64e-06 | 2.97e-04 | 25 |
| GO:00713335 | Stomach | GC | cellular response to glucose stimulus | 24/1159 | 151/18723 | 1.87e-05 | 5.77e-04 | 24 |
| GO:00713225 | Stomach | GC | cellular response to carbohydrate stimulus | 25/1159 | 163/18723 | 2.36e-05 | 6.90e-04 | 25 |
| GO:00425935 | Stomach | GC | glucose homeostasis | 34/1159 | 258/18723 | 2.54e-05 | 7.31e-04 | 34 |
| GO:00335005 | Stomach | GC | carbohydrate homeostasis | 34/1159 | 259/18723 | 2.76e-05 | 7.80e-04 | 34 |
| GO:00081546 | Stomach | GC | actin polymerization or depolymerization | 30/1159 | 218/18723 | 3.29e-05 | 8.94e-04 | 30 |
| GO:19049516 | Stomach | GC | positive regulation of establishment of protein localization | 39/1159 | 319/18723 | 3.79e-05 | 9.76e-04 | 39 |
| GO:00716925 | Stomach | GC | protein localization to extracellular region | 43/1159 | 368/18723 | 4.61e-05 | 1.11e-03 | 43 |
| GO:00093065 | Stomach | GC | protein secretion | 42/1159 | 359/18723 | 5.46e-05 | 1.29e-03 | 42 |
| GO:00355925 | Stomach | GC | establishment of protein localization to extracellular region | 42/1159 | 360/18723 | 5.82e-05 | 1.34e-03 | 42 |
| GO:00016785 | Stomach | GC | cellular glucose homeostasis | 25/1159 | 172/18723 | 5.90e-05 | 1.35e-03 | 25 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GHRL | SNV | Missense_Mutation | c.196N>A | p.Glu66Lys | p.E66K | Q9UBU3 | protein_coding | tolerated(0.12) | possibly_damaging(0.492) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GHRL | SNV | Missense_Mutation | rs767976379 | c.187N>A | p.Gly63Ser | p.G63S | Q9UBU3 | protein_coding | tolerated(0.8) | benign(0.029) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| GHRL | SNV | Missense_Mutation | rs540101934 | c.40N>A | p.Gly14Ser | p.G14S | Q9UBU3 | protein_coding | tolerated(1) | benign(0) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| GHRL | SNV | Missense_Mutation | novel | c.122N>T | p.Ser41Leu | p.S41L | Q9UBU3 | protein_coding | tolerated(0.19) | possibly_damaging(0.448) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GHRL | SNV | Missense_Mutation | novel | c.337G>T | p.Ala113Ser | p.A113S | Q9UBU3 | protein_coding | tolerated(0.23) | benign(0.272) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GHRL | SNV | Missense_Mutation | novel | c.290N>T | p.Ala97Val | p.A97V | Q9UBU3 | protein_coding | tolerated(0.29) | possibly_damaging(0.809) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| GHRL | SNV | Missense_Mutation | rs567867101 | c.173G>A | p.Arg58His | p.R58H | Q9UBU3 | protein_coding | tolerated(0.28) | benign(0) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GHRL | SNV | Missense_Mutation | novel | c.122C>T | p.Ser41Leu | p.S41L | Q9UBU3 | protein_coding | tolerated(0.19) | possibly_damaging(0.448) | TCGA-FI-A2D4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| GHRL | SNV | Missense_Mutation | rs372434370 | c.208N>T | p.Asp70Tyr | p.D70Y | Q9UBU3 | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-PG-A915-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GHRL | SNV | Missense_Mutation | rs756969269 | c.178G>A | p.Glu60Lys | p.E60K | Q9UBU3 | protein_coding | tolerated(0.05) | possibly_damaging(0.689) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51738 | GHRL | DRUGGABLE GENOME | ROFECOXIB | ROFECOXIB | 16868036 | |
| 51738 | GHRL | DRUGGABLE GENOME | RALOXIFENE | RALOXIFENE | 18164562 | |
| 51738 | GHRL | DRUGGABLE GENOME | HUMAN CHORIONIC GONADOTROPIN | 17535999 | ||
| 51738 | GHRL | DRUGGABLE GENOME | PIOGLITAZONE | PIOGLITAZONE | 16682836 | |
| 51738 | GHRL | DRUGGABLE GENOME | Unacylated ghrelin | |||
| 51738 | GHRL | DRUGGABLE GENOME | RISPERIDONE | RISPERIDONE | 18480685 | |
| 51738 | GHRL | DRUGGABLE GENOME | Relamorelin | RELAMORELIN | ||
| 51738 | GHRL | DRUGGABLE GENOME | ARD-07 | MACIMORELIN | ||
| 51738 | GHRL | DRUGGABLE GENOME | PLANT STEROLS | 18066136 | ||
| 51738 | GHRL | DRUGGABLE GENOME | INSULIN | INSULIN | 17449920 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |